In the BioHarmony Drug Report Database

"Preview" Icon

Brodalumab

Siliq, Kyntheum (brodalumab) is an antibody pharmaceutical. Brodalumab was first approved as Siliq on 2017-02-15. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-17 receptor A.

 

Trade Name

 

Kyntheum
 

Common Name

 

brodalumab
 

ChEMBL ID

 

CHEMBL1742996
 

Indication

 

psoriasis
 

Drug Class

 

Monoclonal antibodies: fully human, immunomodulating

Image (chem structure or protein)

Brodalumab structure rendering